Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-09	US$1.170	-1.68%	367,029
26-09-08	US$1.190	-1.65%	348,592
26-09-04	US$1.210	-0.82%	362,983
26-09-03	US$1.220	0.00%	203,326
26-09-02	US$1.220	+1.67%	169,514

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.190USD

Average target price

4.000USD

Spread / Average Target

+236.13%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-09-09 EDT			5-day change	1st Jan Change
1.170 ^USD	-1.68%		-2.50%	-49.79%

08-12	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	69.3M 59.56M 56.07M 51.16M 95.62M 6.59B 96.09M 664M 257M 3.36B 260M 255M 10.64B	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	69.3M 59.56M 56.07M 51.16M 95.62M 6.59B 96.09M 664M 257M 3.36B 260M 255M 10.64B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.39%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	SPRO	Delayed
Tradegate	2HA	Real-time
CBOE	SPRO	Real-time
Boerse Muenchen	2HA	Real-time
Deutsche Boerse AG	2HA	Delayed
Börse Stuttgart	2HA	Delayed

08-12	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-27	Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer	CI
07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
07-14	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI
07-14	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing	MT
07-14	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion	RE
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
06-28	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
06-17	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
06-17	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI

Spero Therapeutics, Inc. Stock

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation : Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript : Spero Therapeutics, Inc.

Analysts' recommendations : Spero Therapeutics, Inc.

Press Releases : Spero Therapeutics, Inc.

News in other languages : Spero Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

09-03	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
09-02	Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-12	Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update	AQ
08-06	Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
08-05	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ

06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Star Warsh
06-18	MORNING BRIEFING - Deutschland/Europa -2-
06-17	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
25-10-21	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 day	-1.68%
1 week	-2.50%
Current month	-4.10%
1 month	-7.14%
3 months	-57.30%
6 months	-49.13%
Current year	-49.79%

1 week	1.17	1.23
1 month	1.17	1.3
Current year	1.08	3.08
1 year	1.08	3.08
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	2025-01-09
Debra Zack CTO	Chief Tech/Sci/R&D Officer	69	2026-07-26
Timothy Keutzer COO	Chief Operating Officer	58	2023-01-31

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	2013-12-31
Patrick Volkert Vink BRD	Director/Board Member	62	2015-08-31
Frank Thomas CHM	Chairman	56	2025-01-09

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/3/26	Debra Zack	Free	Chief Technology Officer	486,986	0.8411%
5/4/26	Esther Rajavelu	Sell	Chief Executive Officer	-25,240	0.0436%
2/6/26	Esther Rajavelu	Sell	Chief Executive Officer	87,917	0.1560%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	-1.68%	-2.50%	-41.35%	-13.97%	69.3M
WUXI APPTEC CO., LTD.	-0.94%	+0.31%	+40.04%	+103.25%	69.19B
ARGENX SE	-0.07%	-2.37%	+33.44%	+78.50%	62.97B
INSMED INCORPORATED	+3.13%	+6.00%	-12.19%	+390.48%	27.27B
BIONTECH SE	-0.54%	-3.74%	-4.41%	-18.31%	24.78B
WUXI BIOLOGICS (CAYMAN) INC.	-0.93%	-1.29%	+25.30%	+16.70%	25.8B
GENMAB A/S	-1.43%	-0.61%	+22.71%	-19.01%	20.11B
PHARMAESSENTIA CORPORATION	-4.27%	+2.67%	+219.02%	+362.48%	18.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.43%	-1.80%	-8.64%	+537.09%	14.88B
EXELIXIS, INC.	+1.14%	+2.53%	+54.76%	+163.82%	14.29B
Average	-0.59%	-0.36%	+32.87%	+160.10%	27.78B
Weighted average by Cap.	-0.39%	-0.76%	+36.86%	+141.66%

	2024	2025
Net sales	47.98M 41.24M 38.82M 35.42M 66.2M 4.56B 66.52M 460M 178M 2.33B 180M 176M 7.37B	66.8M 57.42M 54.05M 49.31M 92.17M 6.35B 92.63M 640M 247M 3.24B 251M 245M 10.26B
Net income	-68.57M -58.93M -55.47M -50.62M -94.61M -6.52B -95.07M -657M -254M -3.32B -257M -252M -10.53B	8.57M 7.37M 6.94M 6.33M 11.83M 815M 11.89M 82.14M 31.75M 416M 32.18M 31.48M 1.32B
Net Debt	-	-